Arctic Bioscience - Report Publication Announcement 2024

Arctic Bioscience - Annual report 2023

Arctic Bioscience has today released its Annual Report 2023, including the Board

of Directors report and financial statements. The report and annual accounts

were approved by the Board of Directors after close of business on 8[th] of

April 2024.

The report is attached to this stock notice and is available on the company's

website.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

Jone R. Slinning

CFO

Mobile: +47 948 75 469

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant